Kiromic BioPharma Inc
shares are gaining Wednesday morning. However, there is no specific news today. During the session, the share price reached $9.22.
Monday morning, the FDA authorized the company's Investigational New Drug (IND) application to initiate a Phase 1 trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).
The company expects to start the trial in Q2 of 2023.
Deltacel is the company's allogeneic, non-engineered, off-the-shelf Gamma Delta T-cell therapy.
The company submitted the IND application in early April.
Kiromic BioPharma stock is gaining on heavy volume, with a session volume of 3.6 million shares traded, compared to the trailing 100-day volume of 164.038K shares.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.